Advaccine Respiratory Syncytial Virus (RSV) Vaccine Phase II trials in Australia
- A Single US$2.15-Million Injection to Block 90% of Cancer Cell Formation
- WIV: Prevention of New Disease X and Investigation of the Origin of COVID-19
- Why Botulinum Toxin Reigns as One of the Deadliest Poisons?
- FDA Approves Pfizer’s One-Time Gene Therapy for Hemophilia B: $3.5 Million per Dose
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
Advaccine Respiratory Syncytial Virus (RSV) Vaccine Candidate Completed Vaccination of the First Participants of Phase II Clinical trials in Australia
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- What is the difference between Atorvastatin and Rosuvastatin?
- How long can the patient live after heart stent surgery?
Advaccine Respiratory Syncytial Virus (RSV) Vaccine Phase II trials in Australia.
On June 4, 2021, Advaccine Biopharmaceuticals announced that the candidate vaccine ADV110 in its research and development pipeline to prevent respiratory syncytial virus (RSV) infection caused diseases has successfully completed Phase II in Australia The first batch of subjects in clinical research were vaccinated.
The trial is a double-center, randomized, double-blind, placebo-controlled, dose-exploratory study, recruiting healthy subjects aged 60 to 80, and aims to evaluate the safety and immunogenicity of ADV110.
Previously, Advaccine completed the phase I clinical trial of ADV110 in Australia. The results of the study showed that ADV110 has good safety and tolerability at low doses, high doses, as well as single and double vaccination.
Most subjects showed a significant antibody response, with the low-dose group reaching 90% and the high-dose group reaching 100%.
Dr. Wang Bin, Chairman of the Board of Directors of Advaccine, said:
“There is a huge unmet need for safe and effective vaccines to deal with respiratory diseases and complications caused by RSV virus infection. We believe that this phase II study of the ADV110 vaccine can further prove Ai Di The safety and immunogenicity of the RSV vaccine containing new adjuvants designed and developed by Advaccine. The company will continue to work hard to provide effective prevention programs for the global public health problems caused by the RSV virus.”
RSV is a common respiratory virus that causes a large number of infections and deaths every year and causes a huge economic burden. There are no vaccines and effective drugs worldwide.
ADV110 independently developed by Advaccine is a candidate protein subunit RSV vaccine containing a novel adjuvant, designed to protect children and the elderly.
The vaccine is one of the most advanced RSV vaccine candidates in the world.
About RSV virus (respiratory syncytial virus)
RSV is a respiratory virus that is spread through the cough or sneeze of an infected person. It usually causes cold-like symptoms. In severe cases, it can develop into pneumonia and bronchitis.
RSV virus can cause infection in people of all ages, especially children, the elderly, and adults with weakened immune functions. Among them, 96% of children under 5 years of age will be infected with RSV.
In 2017, the WHO estimated that the RSV virus causes about 33 million severe respiratory infections each year, resulting in more than 3 million hospitalizations for children under the age of 5 each year, and nearly 60,000 deaths.
In 2019, the global economic burden caused by RSV is approximately US$4.2 billion. However, there are neither effective drugs to treat RSV nor a vaccine available globally.
About Advaccine:
Advaccine is an innovative vaccine company that relies on a mature internal technology platform to develop a high-value preventive and therapeutic vaccine pipeline, and has industrial production capabilities.
Advaccine’s key product pipeline includes potential first vaccines against diseases caused by the new coronavirus (SARS-CoV-2), respiratory syncytial virus (RSV), and hepatitis B virus (HBV), all of which have long medical needs. Unsatisfied disease.
Advaccine is also developing a series of cancer vaccines, including candidate vaccines for virus-related tumors, neo-antigen-based therapeutic vaccines and tumor-associated antigen (TAA) therapeutic vaccines
Advaccine Respiratory Syncytial Virus (RSV) Vaccine Candidate Completed Vaccination of the First Participants of Phase II Clinical trials in Australia
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
